The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors.
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Tempus
Research Funding - Agenus (Inst); Boston Biomedical (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Placon (Inst); Stem Cells, Inc. (Inst); Tempus (Inst)
Travel, Accommodations, Expenses - Japanese Society of Clinical Oncology
 
Sofia de Achaval
Employment - Tvardi Therapeutics
Stock and Other Ownership Interests - Tvardi Therapeutics
Patents, Royalties, Other Intellectual Property - Tvardi Therapeutics
 
Imran Alibhai
Employment - Tvardi Therapeutics
Leadership - Tvardi Therapeutics
Stock and Other Ownership Interests - DNAtrix; Tvardi Therapeutics
Patents, Royalties, Other Intellectual Property - Tvardi Therapeutics
Travel, Accommodations, Expenses - Tvardi Therapeutics
 
Ahmed Omar Kaseb
Honoraria - Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Bristol-Myers Squibb; Exelixis; Merck